C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu

C-Ray Therapeutics receives FDA acceptance for copper-64 file

CHENGDU, China, April 28, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has been listed as active by the U.S. Food and Drug Administration (FDA) under DMF No. 43568. The DMF is now available for reference by radiopharmaceutical developers worldwide in support of IND and NDA submissions. Cu-64: The Next-Generation Diagnostic Radion…

C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu

DMF No. 43568 is now active and available for reference in global IND and NDA submissions CHENGDU, China, April 28, 2026 /PRNewswire/ — C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has been listed as active by the U.S. Food and Drug […]